Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Relevance of Typing HLA-DR7-DQ2

NCT01813383 is registered in ClinicalTrials.gov with Corporacion Parc Tauli as lead sponsor.

NCT NCT01813383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01813383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Relevance of Typing HLA-DR7-DQ2
Lead sponsor
Corporacion Parc Tauli
Phase
Observational
Overall status
Completed
Start date
January 31, 2010
Completion date
March 31, 2013
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease patients following recommendations of espghan, hla-dq2 typing include hla-dr7-dq2 haplotypes